Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0000950170-25-021707·ArriVent BioPharma, Inc.
Schedule 13G ownership disclosure
ArriVent BioPharma, Inc.
Common Stock, par value $0.0001 per share · CUSIP: 0472N1020
Event date: 2025-02-07
- Filing-level shares
- 1,750,000
- Percent of class
- 5.2%
- Novo Holdings A/S
Shares: 1,750,000 · Class: 5.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950170-25-021707
- Form type
- SCHEDULE 13G
- Filer
- ArriVent BioPharma, Inc.
- CIK
- CIK 1868279
- Filed
- Feb 14, 2025
- Reporting period
- Feb 07, 2025
- Description
- Schedule 13G beneficial ownership